Ameritas Investment Partners’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $199K | Hold |
6,697
| – | – | 0.01% | 1264 |
|
|
2025
Q4 | $256K | Sell |
6,697
-669
| -9% | -$21.8K | 0.01% | 1115 |
|
|
2025
Q3 | $176K | Sell |
7,366
-1,144
| -13% | -$21.5K | 0.01% | 1315 |
|
|
2025
Q2 | $126K | Hold |
8,510
| – | – | ﹤0.01% | 1593 |
|
|
2025
Q1 | $152K | Buy |
8,510
+605
| +8% | +$12.3K | 0.01% | 1434 |
|
|
2024
Q4 | $138K | Buy |
7,905
+667
| +9% | +$11.8K | ﹤0.01% | 1568 |
|
|
2024
Q3 | $101K | Hold |
7,238
| – | – | ﹤0.01% | 1770 |
|
|
2024
Q2 | $59.5K | Hold |
7,238
| – | – | ﹤0.01% | 2043 |
|
|
2024
Q1 | $55.8K | Hold |
7,238
| – | – | ﹤0.01% | 2083 |
|
|
2023
Q4 | $65.1K | Hold |
7,238
| – | – | ﹤0.01% | 2008 |
|
|
2023
Q3 | $64.7K | Buy |
7,238
+1,222
| +20% | +$17.2K | ﹤0.01% | 1944 |
|
|
2023
Q2 | $92.4K | Buy |
6,016
+1,074
| +22% | +$19.5K | ﹤0.01% | 1655 |
|
|
2023
Q1 | $111K | Buy |
4,942
+441
| +10% | +$9.37K | ﹤0.01% | 1470 |
|
|
2022
Q4 | $97.4K | Hold |
4,501
| – | – | ﹤0.01% | 1619 |
|
|
2022
Q3 | $110K | Hold |
4,501
| – | – | ﹤0.01% | 1422 |
|
|
2022
Q2 | $109K | Hold |
4,501
| – | – | ﹤0.01% | 1446 |
|
|
2022
Q1 | $116K | Hold |
4,501
| – | – | ﹤0.01% | 1539 |
|
|
2021
Q4 | $140K | Hold |
4,501
| – | – | ﹤0.01% | 1480 |
|
|
2021
Q3 | $109K | Hold |
4,501
| – | – | ﹤0.01% | 1640 |
|
|
2021
Q2 | $66K | Hold |
4,501
| – | – | ﹤0.01% | 2002 |
|
|
2021
Q1 | $112K | Buy |
4,501
+332
| +8% | +$9.17K | ﹤0.01% | 1596 |
|
|
2020
Q4 | $114K | Hold |
4,169
| – | – | 0.01% | 1508 |
|
|
2020
Q3 | $77K | Buy |
4,169
+676
| +19% | +$13.1K | ﹤0.01% | 1591 |
|
|
2020
Q2 | $71K | Hold |
3,493
| – | – | ﹤0.01% | 1618 |
|
|
2020
Q1 | $51K | Hold |
3,493
| – | – | ﹤0.01% | 1651 |
|
|
2019
Q4 | $50K | Hold |
3,493
| – | – | ﹤0.01% | 1928 |
|
|
2019
Q3 | $40K | Hold |
3,493
| – | – | ﹤0.01% | 2012 |
|
|
2019
Q2 | $70K | Hold |
3,493
| – | – | ﹤0.01% | 1715 |
|
|
2019
Q1 | $79K | Hold |
3,493
| – | – | ﹤0.01% | 1625 |
|
|
2018
Q4 | $79K | Hold |
3,493
| – | – | ﹤0.01% | 1546 |
|
|
2018
Q3 | $100K | Hold |
3,493
| – | – | ﹤0.01% | 1571 |
|
|
2018
Q2 | $95K | Buy |
3,493
+366
| +12% | +$9.75K | ﹤0.01% | 1583 |
|
|
2018
Q1 | $70K | Hold |
3,127
| – | – | ﹤0.01% | 1720 |
|
|
2017
Q4 | $66K | Hold |
3,127
| – | – | ﹤0.01% | 1758 |
|
|
2017
Q3 | $76K | Hold |
3,127
| – | – | ﹤0.01% | 1624 |
|
|
2017
Q2 | $61K | Hold |
3,127
| – | – | ﹤0.01% | 1779 |
|
|
2017
Q1 | $58K | Buy |
+3,127
| New | +$61.2K | ﹤0.01% | 1753 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
Ameritas Investment Partners's TVTX Position: Q1 2026 in Review
Ameritas Investment Partners held its Travere Therapeutics (TVTX) position steady in Q1 2026 at 6,697 shares worth $199K. The position accounts for 0.01% of the portfolio, ranked #1264.
Ameritas Investment Partners first reported a position in TVTX in Q1 2017 and has held it in 37 quarters since. The position peaked at $256K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- Ameritas Investment Partners held 6,697 shares of Travere Therapeutics worth $199K as of Q1 2026.
- Ameritas Investment Partners left its Travere Therapeutics share count unchanged in Q1 2026.
- Travere Therapeutics made up 0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1264 holding.
- Ameritas Investment Partners first reported a position in Travere Therapeutics in Q1 2017 and has held it in 37 quarters since.
- Ameritas Investment Partners's Travere Therapeutics position peaked at $256K in Q4 2025.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.